EUVIMEDEUVIMED entdecken
Crossref

Narrative review on the clinical utility of direct bilirubin and bilirubin fractionation in cirrhosis and acute-on-chronic liver failure

Danny Aboujamra, Rakahn Haddadin, Jackson Hoekstra, Victoria Diaz, Yasra Badi, Tajveer Sangha, Zahra Dossaji, Katerina Roma, Robert G. Gish

Translational Gastroenterology and Hepatology · 2026-11 · 11 · 0-0

DOI: 10.21037/tgh-2026-0153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-11. Verfasst von Danny Aboujamra und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: The term "liver function tests" can obscure the distinction between hepatocellular injury and hepatic functional capacity. Total bilirubin (TB) combines fractions with different biological and analytical determinants. This review addresses two separate questions in cirrhosis and acute-on-chronic liver failure (ACLF): how bilirubin fractionation informs mechanistic interpretation, and whether direct bilirubin (DB) or DB-derived measures improve prognosis beyond TB and established severity scores.

Methods

We reviewed human literature published from January 1, 2000 through June 8, 2026 using PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library, without a database language restriction. Targeted reference verification was performed on September 10, 2026. Absolute DB, the direct-to-TB ratio (DB/TB), and composite indices were synthesized separately, with a structured qualitative appraisal of the principal studies.Key Content and Findings: Fractionation helps distinguish predominantly unconjugated from direct-reacting hyperbilirubinemia, but routine DB assays may include albumin-bound delta bilirubin and do not measure conjugated bilirubin exclusively. In the principal head-to-head general cirrhosis study, a single-center retrospective cohort of 983 hospitalized patients, DB showed slightly greater discrimination than TB for 6-month death or transplantation. External validation was absent. Studies of DB/TB, DB-to-albumin ratios (DBARs), and other composite models are not replications of that comparison. Associations in ACLF and cholestatic disease remain dependent on the population, definition, assay, and outcome; added calibration or clinical decision value has not been established.

Conclusions

Selective fractionation is useful for interpreting unexplained hyperbilirubinemia or suspected cholestasis. Current evidence does not justify replacing TB in established prognostic scores or measuring DB with every hepatic panel. Prognostic adoption requires external validation against contemporary models, platform-specific analytical validation, and demonstration that a defined testing pathway improves decisions and outcomes.

Zitieren

APA

Aboujamra, D., Haddadin, R., Hoekstra, J., Diaz, V., Badi, Y., Sangha, T., Dossaji, Z., Roma, K., & Gish, R. G. (2026). Narrative review on the clinical utility of direct bilirubin and bilirubin fractionation in cirrhosis and acute-on-chronic liver failure. Translational Gastroenterology and Hepatology, 11, 0-0. https://doi.org/10.21037/tgh-2026-0153

Vancouver

Aboujamra D, Haddadin R, Hoekstra J, Diaz V, Badi Y, Sangha T, et al. Narrative review on the clinical utility of direct bilirubin and bilirubin fractionation in cirrhosis and acute-on-chronic liver failure. Translational Gastroenterology and Hepatology. 2026;11:0-0. doi:10.21037/tgh-2026-0153

BibTeX
@article{Aboujamra2026,
  author = {Aboujamra, Danny and Haddadin, Rakahn and Hoekstra, Jackson and Diaz, Victoria and Badi, Yasra and Sangha, Tajveer and Dossaji, Zahra and Roma, Katerina and Gish, Robert G.},
  title = {Narrative review on the clinical utility of direct bilirubin and bilirubin fractionation in cirrhosis and acute-on-chronic liver failure},
  journal = {Translational Gastroenterology and Hepatology},
  year = {2026},
  volume = {11},
  pages = {0--0},
  doi = {10.21037/tgh-2026-0153}
}
Kostenlos starten →